These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21915270)

  • 41. Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study.
    Trieu MC; Jul-Larsen Å; Sævik M; Madsen A; Nøstbakken JK; Zhou F; Skrede S; Cox RJ
    Clin Infect Dis; 2019 Jan; 68(3):382-392. PubMed ID: 29893797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic.
    Bandaranayake D; Huang QS; Bissielo A; Wood T; Mackereth G; Baker MG; Beasley R; Reid S; Roberts S; Hope V;
    PLoS One; 2010 Oct; 5(10):e13211. PubMed ID: 20976224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroprevalence study in Vojvodina (Serbia) following 2009 pandemic influenza A(H1N1)V.
    Petrović V; Reguljev Z; Nedeljković J; Ristić M
    Srp Arh Celok Lek; 2012; 140(11-12):751-5. PubMed ID: 23350250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemic.
    Magalhaes I; Eriksson M; Linde C; Muhammad R; Rane L; Ambati A; Axelsson-Robertson R; Khalaj B; Alvarez-Corrales N; Lapini G; Montomoli E; Linde A; Pedersen NL; Maeurer M
    BMC Infect Dis; 2014 Jun; 14():319. PubMed ID: 24916787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India.
    Tandale BV; Pawar SD; Gurav YK; Chadha MS; Koratkar SS; Shelke VN; Mishra AC
    BMC Infect Dis; 2010 Aug; 10():255. PubMed ID: 20738878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
    Li YP; Li W; Liang XF; Liu Y; Huang XC; Li CG; Li RC; Wang JZ; Wang HQ; Yin WD
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1297-307. PubMed ID: 23134570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
    Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
    N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?
    Allwinn R; Geiler J; Berger A; Cinatl J; Doerr HW
    Med Microbiol Immunol; 2010 May; 199(2):117-21. PubMed ID: 20162304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.
    Chan KH; To KK; Hung IF; Zhang AJ; Chan JF; Cheng VC; Tse H; Che XY; Chen H; Yuen KY
    Clin Vaccine Immunol; 2011 May; 18(5):867-73. PubMed ID: 21411604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
    Skowronski DM; Janjua NZ; De Serres G; Purych D; Gilca V; Scheifele DW; Dionne M; Sabaiduc S; Gardy JL; Li G; Bastien N; Petric M; Boivin G; Li Y
    J Infect Dis; 2012 Dec; 206(12):1852-61. PubMed ID: 22872731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cumulative incidence of pandemic influenza A (H1N1) 2009 by a community-based serological cohort study in Selenghe Province, Mongolia.
    Burmaa A; Tsatsral S; Odagiri T; Suzuki A; Oshitani H; Nymadawa P
    Influenza Other Respir Viruses; 2012 Nov; 6(6):e97-e104. PubMed ID: 22329794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
    Ahmed SS; Schur PH; MacDonald NE; Steinman L
    J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.